During the last session, Regulus Therapeutics Inc (NASDAQ:RGLS)’s traded shares were 32.42 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $1.50, reflecting an intraday gain of 16.28% or $0.21. The 52-week high for the RGLS share is $3.00, that puts it down -100.0 from that peak though still a striking 44.67% gain since the share price plummeted to a 52-week low of $0.83. The company’s market capitalization is $99.37M, and the average intraday trading volume over the past 10 days was 3.43 million shares, and the average trade volume was 476.23K shares over the past three months.
Regulus Therapeutics Inc (RGLS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. RGLS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Regulus Therapeutics Inc (RGLS) registered a 16.28% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.28% in intraday trading to $1.50, hitting a weekly high. The stock’s 5-day price performance is 10.29%, and it has moved by 10.29% in 30 days. Based on these gigs, the overall price performance for the year is -46.81%. The short interest in Regulus Therapeutics Inc (NASDAQ:RGLS) is 2.04 million shares and it means that shorts have 6.49 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 40.21%. While earnings are projected to return -42.89% in 2025, the next five years will return -3.70% per annum.
RGLS Dividends
Regulus Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Regulus Therapeutics Inc insiders own 2.18% of total outstanding shares while institutional holders control 82.48%, with the float percentage being 84.32%. FEDERATED HERMES, INC. is the largest shareholder of the company, while 93.0 institutions own stock in it. As of 2024-06-30, the company held over 12.85 million shares (or 19.9374% of all shares), a total value of $22.94 million in shares.
The next largest institutional holding, with 6.25 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 9.6952% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of Regulus Therapeutics Inc (RGLS) shares are Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund owns about 7.88 shares. This amounts to just over 11.90 percent of the company’s overall shares, with a $11.82 million market value. The same data shows that the other fund manager holds slightly less at 2.5, or about 3.78% of the stock, which is worth about $3.75 million.
